Another CMO mishap stings Cubist

Cubist Pharmaceuticals ($CBST) is recalling 100 lots of its banner antibiotic Cubicin after problems with a contract manufacturer, its third such issue in 12 months. The latest and largest recall follows one from August 2013 and another in April, each plagued by the discovery of glass particles in the injectable treatment and each blamed on a CMO. More

Suggested Articles

The money will be used to expand its footprint in both China and the U.S., including a new R&D operation in Boston.

The CRO will transfer most of its Pennsylvania-based biologics laboratory functions to a new, 73,000-square-foot site on Devon Park in Wayne.

Monoclonal antibodies developer Xencor extended a strategic alliance formed in 2016 with Selexis with four commercial license agreements.